NeurAxis Highlights Pediatric Post-Concussion Clinical Study
CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Month: August 2023
LifeBridge Health selects NRC Health as its new patient experience partner
LINCOLN, Neb., Aug. 29, 2023 (GLOBE NEWSWIRE) -- LifeBridge Health has selected NRC Health to be its partner in providing Human Understanding® through...
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced...
Digipath Announces Record Earnings of $292,533 for Recent Quarter Ended June 30
Digipath, Inc. High capacity LCMS-QQQ for testing pesticidesLab Operations has Seen a Consistent Uptick in Sample Flow LAS VEGAS, NV,...
Jupiter Wellness Appoints Jarrett Boon, as COO
Boon was one of the original thought leaders and investors in LifeLock, which was subsequently acquired for $2.3 billion.He will...
Evaxion announces Executive Management Changes to strengthen the AI-strategy
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulationsPRINCETON,...
CMS grants reimbursement code for the Polarean XENOVIEW™ MRI Technology
The code is effective as of October 1, 2023Durham, NC, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX), a...
Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.
Ocean’s small molecule candidate significantly controls fibrosis progression in idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing...
Olink to participate in September investor events
UPPSALA, Sweden, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management...
Vaxxinity to Present at Upcoming Investor Conferences in September
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of...
InnovAge to Announce Fiscal Fourth Quarter 2023 Financial Results and Host Conference Call Tuesday, September 12, 2023
DENVER, Aug. 29, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in...
Better Life Partners Raises $26.5 Million in Series B Financing to Amplify and Scale its Hybrid Whole-Health Solutions for Substance Use Disorders
Funding will expand company’s technology-enabled, alternate-payment care model, bringing its innovative and effective approach to more people in needBOSTON, Aug....
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of...
Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Independent Safety Committee approves next cohort dosing of RECCE® 327 (R327) at two faster infusion rates of 3,000mg via IV...
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a...
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with ZORYVEZORYVE is a once-daily, steroid-free...
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
MIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology...
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid...
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™...